pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·37m ago·1 min read
save

K Health is eyeing an IPO by 2029

K Health is gearing up for a future public-market debut, CEO Allon Bloch said after a recent raise. The virtual care company, which uses AI to help patients and clinicians sort through and act on ...

Sep 1, 2026·read at Endpoints ↗

K Health CEO Allon Bloch September 1, 2026 09:00 AM EDT Health Tech K Health is eye­ing an IPO by 2029 Ngai Yeung Health Tech Reporter K Health is gear­ing up for a fu­ture pub­lic-mar­ket de­but, CEO Al­lon Bloch said af­ter a re­cent raise. The vir­tu­al care com­pa­ny, which us­es AI … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
86 words · retrieved 4m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoNovartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggestEndpoints
  • 12h agoARCH Venture Partners targets $3 billion raise for latest fundEndpoints
  • 13h agoThree deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also pausedEndpoints
  • 17h agoTrump announces nine new MFN drug pricing dealsEndpoints
  • 21h agoTake the Q3 Biopharma Sentiment Survey (BPSI)Endpoints